Literature DB >> 19300963

Isolated, relapsing and progressive demyelinating diseases of the central nervous system.

Axel Petzold1.   

Abstract

Many patients ask, "Can I get this again?" (a relapse) and "How bad is it? Will I end up in a wheelchair?" (severity/progression). These two questions guide this brief review of the clinical spectrum of demyelinating diseases of the central nervous system.

Entities:  

Mesh：

Year:  2008        PMID： 19300963     DOI： 10.1007/s00415-008-6013-y

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  74 in total

1.  Idiopathic transverse myelitis.

Authors:  Chitra Krishnan; Douglas A Kerr
Journal:  Arch Neurol       Date:  2005-06

Review 2.  Secondary progressive multiple sclerosis: current knowledge and future challenges.

Authors:  Marco Rovaris; Christian Confavreux; Roberto Furlan; Ludwig Kappos; Giancarlo Comi; Massimo Filippi
Journal:  Lancet Neurol       Date:  2006-04       Impact factor: 44.182

3.  Four-year follow-up of a case of acute multiple sclerosis of the Marburg type.

Authors:  F Giubilei; A Sarrantonio; P Tisei; C Gasperini; M Salvetti
Journal:  Ital J Neurol Sci       Date:  1997-06

4.  Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up.

Authors:  Petra Nilsson; Elna-Marie Larsson; Pia Maly-Sundgren; Roland Perfekt; Magnhild Sandberg-Wollheim
Journal:  J Neurol       Date:  2005-03-22       Impact factor: 4.849

5.  Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients.

Authors:  Albert Saiz; Luigi Zuliani; Yolanda Blanco; Bruno Tavolato; Bruno Giometto; Francesc Graus
Journal:  J Neurol       Date:  2007-04-02       Impact factor: 4.849

6.  Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.

Authors:  Brian G Weinshenker; Dean M Wingerchuk; Sandra Vukusic; Linda Linbo; Sean J Pittock; Claudia F Lucchinetti; Vanda A Lennon
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

Review 7.  Balo's concentric sclerosis diagnosed intravitam on brain biopsy.

Authors:  M Nandini; M Gourie-Devi; S K Shankar; V B Mustare; V Ravi
Journal:  Clin Neurol Neurosurg       Date:  1993-12       Impact factor: 1.876

Review 8.  Optic neuritis and multiple sclerosis.

Authors:  Gordon T Plant
Journal:  Curr Opin Neurol       Date:  2008-02       Impact factor: 5.710

Review 9.  Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis.

Authors:  David Miller; Frederik Barkhof; Xavier Montalban; Alan Thompson; Massimo Filippi
Journal:  Lancet Neurol       Date:  2005-05       Impact factor: 44.182

Review 10.  Management of acute optic neuritis.

Authors:  S J Hickman; C M Dalton; D H Miller; G T Plant
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321
View more
  4 in total

1.  Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis.

Authors:  Elke Voss; Peter Raab; Corinna Trebst; Martin Stangel
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

2.  Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

Authors:  Alberto Spalice; Pasquale Parisi; Laura Papetti; Francesco Nicita; Fabiana Ursitti; Francesca Del Balzo; Enrico Properzi; Alberto Verrotti; Martino Ruggieri; Paola Iannetti
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

3.  Axonal damage in the making: neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter.

Authors:  A Petzold; D J Tozer; K Schmierer
Journal:  Exp Neurol       Date:  2011-09-17       Impact factor: 5.330

4.  Acquired demyelinating disorders of central nervous system: A pediatric cohort.

Authors:  Sheffali Gulati; Biswaroop Chakrabarty; Atin Kumar; Puneet Jain; Harsh Patel; Lokesh Saini
Journal:  Ann Indian Acad Neurol       Date:  2015-09       Impact factor: 1.383
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.